BTIG Research Issues Positive Forecast for Medtronic (NYSE:MDT) Stock Price

Key Points

• BTIG Research raised Medtronic’s price target from $91 to $100 and maintained a “buy” rating, implying 7.82% potential upside. Analysts collectively rate the stock “Moderate Buy,” with a consensus target of $100.17.
• Medtronic beat quarterly expectations with adjusted EPS of $1.45 versus $1.39 expected and revenue of $9.76 billion, up 13.7% year over year. Management raised fiscal 2027 guidance to $5.94–$6.00 EPS and 7.25%–7.75% organic revenue growth.
• Shares rose 2.3% to $92.75, although second-quarter EPS guidance of $1.32–$1.34 was slightly below consensus and planned robotics investments may create near-term execution risks.

Medtronic (NYSE:MDT - Get Free Report) had its price target boosted by equities research analysts at BTIG Research from $91.00 to $100.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the medical technology company's stock. BTIG Research's price target would indicate a potential upside of 7.82% from the company's current price.

Several other analysts also recently commented on MDT. TD Cowen raised their price objective on shares of Medtronic from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday. Piper Sandler reiterated a "neutral" rating on shares of Medtronic in a research report on Monday, August 10th. Weiss Ratings reissued a "hold (c)" rating on shares of Medtronic in a research note on Tuesday, August 18th. Wall Street Zen upgraded shares of Medtronic from a "hold" rating to a "buy" rating in a report on Saturday, July 18th. Finally, Robert W. Baird decreased their price target on shares of Medtronic from $93.00 to $85.00 and set a "neutral" rating for the company in a research note on Thursday, June 4th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $100.17.

Medtronic Trading Up 2.3%

Shares of MDT traded up $2.10 during trading hours on Tuesday, hitting $92.75. 10,570,797 shares of the stock were exchanged, compared to its average volume of 8,856,479. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The business has a 50-day moving average of $85.81 and a 200-day moving average of $85.48. The firm has a market capitalization of $118.71 billion, a P/E ratio of 24.80, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. Medtronic's revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts expect that Medtronic will post 5.94 EPS for the current year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.27% of the company's stock.

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently made changes to their positions in MDT. Ipsen Advisor Group LLC increased its holdings in Medtronic by 1.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company's stock worth $572,000 after purchasing an additional 101 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company's stock worth $3,120,000 after buying an additional 101 shares in the last quarter. Rossby Financial LCC grew its holdings in Medtronic by 5.1% during the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company's stock worth $211,000 after buying an additional 107 shares in the last quarter. Wealthspire Retirement LLC raised its position in Medtronic by 5.0% in the 4th quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company's stock valued at $232,000 after buying an additional 114 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. raised its position in Medtronic by 2.0% in the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 6,043 shares of the medical technology company's stock valued at $622,000 after buying an additional 117 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported adjusted earnings of $1.45 per share, above the $1.39 consensus estimate, while revenue rose 13.7% year over year to $9.76 billion, exceeding expectations of approximately $9.55 billion. Growth was broad-based across cardiovascular, neuroscience, medical surgical and diabetes businesses. Medtronic Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Cardiovascular revenue climbed 19.5% on reported growth, supported by demand for devices used in complex procedures. Neuroscience, medical surgical and diabetes revenue also grew at double-digit rates, reinforcing the company’s growth outlook. Medtronic boosts fiscal 2027 forecasts on heart device demand
• Positive Sentiment: Management raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75% and set adjusted EPS guidance at $5.94-$6.00, citing improved margins, portfolio strength and newer growth platforms. Medtronic reports first quarter fiscal 2027 results
• Positive Sentiment: Medtronic committed approximately $700 million to a partnership with Cornerstone Robotics, gaining distribution rights for the Sentire surgical system in select markets outside the U.S. The company also agreed to invest up to $80 million in Pi-Cardia to support complex transcatheter aortic valve replacement procedures. These moves broaden its robotics and structural-heart offerings. Medtronic Announces Strategic Partnership with Cornerstone Robotics
• Positive Sentiment: Unusually heavy call-option activity and generally favorable analyst opinions, along with Medtronic’s dividend yield above 3%, added to the constructive investor sentiment.
• Neutral Sentiment: The stock showed relative strength even as broader U.S. markets traded lower, suggesting the earnings beat and raised outlook were outweighing broader risk-off conditions.
• Negative Sentiment: Second-quarter fiscal 2027 EPS guidance of $1.32-$1.34 was slightly below the $1.35 consensus estimate, and the sizeable robotics investment could increase near-term execution and integration risks.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source